Product Reports Resources Pricing Login Book a demo

Ascendis Pharma

Biotech & Life Sciences · Gentofte Municipality, Denmark · Founded 2007 · IPO 2015

Long-acting prodrug therapies for rare endocrine diseases

Valuation $16B
Revenue $1.48B
EBITDA $424M
Power Law Decacorn$10B+ valuation tier Thoroughbred$100M+ revenue

Talent graph

Ascendis Pharma's talent

Book a demo to see the people
Employees mapped 1,417 incl. 3 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

8 investors on Ascendis Pharma's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage
Sofinnova Partners
Gilde Healthcare
Series B+ 6 investors entered at this stage
Rock Springs Capital
OrbiMed
RA Capital Management
Vivo Capital
Sofinnova Investments
Venrock

Global footprint

Where Ascendis Pharma has talent and traffic

Workforce by country
17 countries with
team presence
🇩🇰 Denmark49.2%
🇺🇸 United States33.8%
🇩🇪 Germany8.2%
🇫🇷 France1.8%
🇪🇸 Spain1.6%
Top 5 of 17 shown
Web traffic by country
23K monthly visits
across markets
🇺🇸 United States37.4%
🏳️ Korea10.9%
🏳️ Republic of7.4%
🇫🇷 France6.5%
🇬🇧 United Kingdom5.7%
Top 5 markets shown

Patent intelligence

$234M patent portfolio · 112 active families

Estimated portfolio value
$234M
1.4% of market cap · 2.1× smaller than top peer Genmab ($488M)
112 active patent families
Where Ascendis Pharma innovates Biological activityCovalent modifierMedicinal chemistryMoietyOrganic chemistry

Where Ascendis Pharma concentrates vs peers

Each axis is a top-10 topic across Ascendis Pharma and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Ascendis Pharma's 3 investments and acquisitions.

Every disclosed deal where Ascendis Pharma appeared as a backer or acquirer, 2018–2023. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Ascendis Pharma's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Ascendis Pharma deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Ascendis Pharma's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about Ascendis Pharma

        An AI-synthesized read of the highest-engagement posts about Ascendis Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Ascendis Pharma on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles